GET DAILY SIGNALSEvaxion A/S (EVAX): Is a Move to $12 With +300% Upside Realistic?
Key Takeaways
- The central target of $12 is the arithmetic mean of four verified analyst price targets — roughly $9 to $16 — rounded from a calculated mean of about $11.50.
- At a latest verified price near $3.00, reaching $12 implies roughly a 300% upside, which is a very large move by any standard.
- Coverage is uniformly bullish, with a "Strong Buy" consensus and no Sell or Hold ratings among the firms reviewed.
- The strongest support comes from Evaxion's AI-driven pipeline, the Phase 2b EVX-01 melanoma program, and consistent Buy ratings from H.C. Wainwright, Lake Street, Edward Jones, and JonesTrading.
- The biggest risks are a negative EPS, limited cash, ongoing losses, possible share dilution, and high single-stock volatility typical of small-cap biotech.
- You can explore more on the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For automated insights across many securities, explore Trending AI Robots.
Analyst Price Targets and Consensus View
The $12 central target is calculated from four individually verified analyst price targets. H.C. Wainwright's Swayampakula Ramakanth holds a Buy with a $16 target, raised from $14 in September 2025 and reiterated in early 2026. Lake Street's Thomas Flaten rates the stock Buy with an $11 target, raised from $6 in October 2025. Edward Jones initiated coverage with a Buy and a $10 target in late October 2025, while JonesTrading also holds a Buy rating near the low end of the range at about $9. The four targets average roughly $11.50, which rounds to a clean central target of $12.
The approximate range of $9 to $16 is notably wide, reflecting genuine disagreement about how much the market should pay for a pre-revenue-stage, AI-enabled immunotherapy pipeline. The most bullish view, H.C. Wainwright's $16, effectively prices in meaningful clinical progress for EVX-01, while the lower targets embed more conservative assumptions about data timing, financing, and execution risk. Notably, all four firms lean positive, so there is no published bearish target in the current set — the disagreement is about magnitude, not direction. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The latest verified close is $3.00 (early November 2026), within a 52-week range of $2.71 to $6.92. Reaching $12 would require a roughly 300% gain, which is a very large move. The stock trades far below its 52-week high set around December 2025, and its market capitalization is only about $25 million — small even by clinical-stage biotech standards.
Financially, EVAX reported trailing twelve-month revenue of roughly $7.5 million with a net loss and a diluted EPS of about -$1.00, and roughly $14 million in cash in the most recent quarter. That means the path to $12 cannot be driven by current earnings; it would have to come from re-rating on clinical data, partnership or licensing news, or a successful capital raise that removes near-term financing overhang. The company's own AI platform, which generated its revenue growth, is a differentiating narrative, but it does not yet translate into profitability.
What Could Support a Move Toward the Target
- Clinical catalysts: EVX-01 is in a global Phase 2b trial for advanced melanoma, and positive efficacy or safety data could materially re-rate the shares.
- Analyst conviction: every covering firm reviewed holds a Buy rating, and H.C. Wainwright raised its target to $16, signaling sustained confidence in the pipeline.
- Revenue momentum: trailing revenue grew more than 100% year over year, albeit from a very small base, demonstrating early commercial traction for the AI platform.
- Re-rating potential: at roughly a $25 million market cap, even modest positive developments could drive outsized percentage moves given the low share price.
What Could Prevent the Target From Being Reached
- Clinical risk: a disappointing EVX-01 readout or trial delay would likely compress the valuation sharply, as the thesis depends heavily on this single asset.
- Capital constraints: roughly $14 million in cash against ongoing losses raises the risk of dilution or dilutive financing, which can pressure a low-priced stock.
- Execution and competition: the immuno-oncology field is crowded, and Evaxion must demonstrate that its AI-designed candidates are meaningfully differentiated.
- Small-cap volatility: with a thin float and low average liquidity, the stock can swing on limited news, and the 52-week range shows it has already given back substantial prior gains.
Technical Levels and Market Structure
Near $3.00, EVAX sits just above its 52-week low of $2.71, which now acts as the most important nearby support level; a decisive break below it would signal further downside. On the upside, the prior 52-week high around $6.92 represents a major resistance level that would need to be reclaimed before the stock could attempt a move toward double digits. Psychological levels at $5 and $10 may also act as intermediate hurdles. The current structure — trading near the bottom of a wide range after a steep decline — underscores that any move toward $12 would require a sustained trend reversal, not just a short-term bounce.
Time Horizon and What Investors Should Monitor
Analyst price targets for Evaxion typically reflect a roughly 12-month research horizon, though the wide $9-to-$16 range shows analysts weight near-term catalysts very differently. Investors should monitor EVX-01 Phase 2b data updates, upcoming quarterly results and any updated guidance on cash runway, new partnership or licensing announcements, and any revisions to analyst targets or ratings. Financing developments, including potential offerings, are equally important given the company's cash position. From what I see, this is important because clinical and financing updates will likely drive the next significant moves.
Final Assessment
Can Evaxion reach $12? The question depends far more on clinical milestones than on anything in the income statement. The $12 central target, derived from four Buy-rated analyst targets ranging from about $9 to $16, implies a roughly 300% advance from the current $3.00 price — a very large move. The bullish case rests on EVX-01's Phase 2b melanoma data and the company's AI platform, while the principal obstacles are clinical uncertainty, a limited cash runway, dilution risk, and the stock's demonstrated small-cap volatility. With no bearish targets published but a wide bullish-to-cautious spread, investors should watch clinical readouts and financing news closely. Nothing here guarantees the target will be reached.
Exploring AI Tools for Trading Insights
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals provide a practical way to monitor volatile names such as EVAX. I use them to track shifting trends and momentum in real time, helping me stay on top of potential changes without relying solely on manual analysis. This approach has been useful for spotting opportunities in small-cap biotech where timing matters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EVAX's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for EVAX moved out of overbought territory on October 21, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In 28 of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVAX as a result. In 77 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EVAX turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
EVAX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EVAX crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EVAX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVAX advanced for three days, in 191 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 89 of 97 cases where EVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.840) is normal, around the industry mean (3.498). P/E Ratio (-6.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.452) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. EVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology